The American Society of Hematology (ASH) has announced the appointment of Dr. Andrew Roberts as the new editor-in-chief of Blood, ASH’s flagship peer-reviewed journal. Dr. Roberts, a clinical hematologist at both the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre in Australia, will begin his five-year term on January 1, 2025, succeeding current editor-in-chief, Dr. Nancy Berliner.
Dr. Roberts brings extensive experience in both clinical practice and hematologic research. He leads translational research at the Walter and Eliza Hall Institute of Medical Research, where he holds the prestigious Metcalf Chair of Leukemia Research at the University of Melbourne. His work focuses on the development of blood cancers such as leukemia and lymphoma, particularly exploring resistance to advanced therapies. He was instrumental in the development of venetoclax, the first BCL-2 inhibitor used to treat leukemia, which marked a breakthrough in blood cancer treatment.
Having served as deputy editor of Blood for the past five years, Dr. Roberts has already made substantial contributions to the journal. Alongside Dr. Berliner, he helped launch the Blood podcast, which highlights top articles weekly, and standardized the journal’s visual abstracts to increase the accessibility of its research. These innovations contributed to Blood’s rising impact factor, reaching 21.0 in 2023, and strengthened its position as the most-cited journal in hematology.
Since its inception in 1946, Blood has been the leading publication for peer-reviewed research in hematology, offering a platform for significant advances in laboratory, translational, and clinical investigations. Today, the Blood journals continue to be the world’s most comprehensive source for peer-reviewed hematology research, reaching researchers and clinicians globally.
Click here to read the original press release.
